(LB01-21-25) A Bio-IntelligenceTM Platform for High Throughput Discovery and In Vivo Validation of Synergistic Bioactives

Objectives: Despite the recognized benefits of combining bioactive ingredients to support human health, rational selection of bioactive combinations with synergy is a major challenge. Current cell-based screening lacks physiological relevance, while rodent models are unsuitable for high-throughput screening. Thus, our objective is to develop a scalable and human-relevant approach that relies on evolutionarily conserved molecular pathways to accelerate combination bioactive discovery and validation.

Methods: NemaLife’s Bio-Intelligence™ platform integrates C. elegans screening with relevant readouts and transcriptomics-driven combination prioritization. Examining the evolutionarily conserved pathways in C. elegans and humans, the Bio-Intelligence^TM platform is optimized for six health indications including metabolic health, muscle performance, stress resilience, gut health, cognitive health and longevity. The capability of the Bio-Intelligence platform is demonstrated by development of a new phytonutrient combination NL100P3 that improves metabolic health, with efficacy that is higher than anti-obesity drugs.

Results: NemaLife’s Bio-Intelligence^TM platform integrates microfluidics chips for multi-day C. elegans studies, visual AI for quantitative phenotypic analysis and worm-to-human bioinformatics tools for molecular pathway analysis. To develop a bioactive combination for metabolic health, individual phytonutrients and their combinations were screened for improvements in C. elegans longevity in the presence of a chronic obesogenic diet. NL100P3 exhibited synergy in enhancing metabolic longevity compared to individual bioactives, demonstrating a 40% improvement over the widely used anti-obesity drug semaglutide. NL100P3 suppressed key metabolic genes to mitigate metabolic stress-induced changes and modulated critical pathways involved in energy balance, mitochondrial function, and cellular resilience.

Conclusions: NemaLife’s Bio-Intelligence^TM platform enables rapid discovery and in vivo validation of bioactives across various health benefits and facilitates the rational design of synergistic combinations. This approach could lead to a new generation of multi-ingredient products to improve human health and wellness.

Funding Sources: NemaLife Inc.